Phase 1Active, not recruiting
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Academic or other)
- Enrolment
- 31 enrolled
- Conditions
- High Risk Cancer; Pancreatic Cancer
- Interventions
- Cohort A: Patients at high risk of developing pancreatic cancer.; Cohort B: Patients must have evidence of a pancreatic cystic neoplasm
- Ages
- adults, older adults
- Registry
- NCT05013216
From the registry
This Phase 1 study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine with poly-ICLC adjuvant for patients who have been identified to be at risk of developing pancreatic cancer.
Primary outcomes
- Number of participants experiencing study drug-related toxicities
- Maximal percentage of change of interferon (IFN-γ) producing mutant-KRAS-specific CD8 and CD4 T cells